420 related articles for article (PubMed ID: 32467570)
1. Nanomedicine-based immunotherapy for central nervous system disorders.
Hanif S; Muhammad P; Chesworth R; Rehman FU; Qian RJ; Zheng M; Shi BY
Acta Pharmacol Sin; 2020 Jul; 41(7):936-953. PubMed ID: 32467570
[TBL] [Abstract][Full Text] [Related]
2. Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.
Guo ZH; Khattak S; Rauf MA; Ansari MA; Alomary MN; Razak S; Yang CY; Wu DD; Ji XY
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770950
[TBL] [Abstract][Full Text] [Related]
3. Targeting specific cells in the brain with nanomedicines for CNS therapies.
Zhang F; Lin YA; Kannan S; Kannan RM
J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
[TBL] [Abstract][Full Text] [Related]
4. Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases.
Luo M; Lee LKC; Peng B; Choi CHJ; Tong WY; Voelcker NH
Adv Sci (Weinh); 2022 Sep; 9(26):e2201740. PubMed ID: 35851766
[TBL] [Abstract][Full Text] [Related]
5. Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting.
Muldoon LL; Tratnyek PG; Jacobs PM; Doolittle ND; Christoforidis GA; Frank JA; Lindau M; Lockman PR; Manninger SP; Qiang Y; Spence AM; Stupp SI; Zhang M; Neuwelt EA
AJNR Am J Neuroradiol; 2006 Mar; 27(3):715-21. PubMed ID: 16552023
[TBL] [Abstract][Full Text] [Related]
6. Advances in nanomedicines for diagnosis of central nervous system disorders.
Zhang X; Zhou J; Gu Z; Zhang H; Gong Q; Luo K
Biomaterials; 2021 Feb; 269():120492. PubMed ID: 33153757
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.
Soni S; Ruhela RK; Medhi B
Adv Pharm Bull; 2016 Sep; 6(3):319-335. PubMed ID: 27766216
[No Abstract] [Full Text] [Related]
8. A Comprehensive Review on Nanomedicine: Promising Approach for Treatment of Brain Tumor through Intranasal Administration.
Bahadur S; Prakash A
Curr Drug Targets; 2023; 24(1):71-88. PubMed ID: 36278468
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnology-based drug delivery for central nervous system disorders.
Nguyen TT; Dung Nguyen TT; Vo TK; Tran NM; Nguyen MK; Van Vo T; Van Vo G
Biomed Pharmacother; 2021 Nov; 143():112117. PubMed ID: 34479020
[TBL] [Abstract][Full Text] [Related]
10. Immunology and immunotherapy in neurosurgical disease.
Prins RM; Liau LM
Neurosurgery; 2003 Jul; 53(1):144-52; discussion 152-3. PubMed ID: 12823883
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
[TBL] [Abstract][Full Text] [Related]
12. Personalized nanomedicine for CNS diseases.
Kaushik A; Jayant RD; Bhardwaj V; Nair M
Drug Discov Today; 2018 May; 23(5):1007-1015. PubMed ID: 29155026
[TBL] [Abstract][Full Text] [Related]
13. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
Zhao X; Ye Y; Ge S; Sun P; Yu P
Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicine and its application in treatment of microglia-mediated neuroinflammation.
Baby N; Patnala R; Ling EA; Dheen ST
Curr Med Chem; 2014; 21(37):4215-26. PubMed ID: 25039775
[TBL] [Abstract][Full Text] [Related]
15. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases.
Zhou X; Smith QR; Liu X
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jul; 13(4):e1695. PubMed ID: 33470550
[TBL] [Abstract][Full Text] [Related]
16. Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.
Kumar NN; Pizzo ME; Nehra G; Wilken-Resman B; Boroumand S; Thorne RG
Bioconjug Chem; 2018 Dec; 29(12):3937-3966. PubMed ID: 30265523
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicines for the Treatment of CNS Diseases.
Reynolds JL; Mahato RI
J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
[TBL] [Abstract][Full Text] [Related]
18. Application of Nanomedicine to the CNS Diseases.
Carradori D; Gaudin A; Brambilla D; Andrieux K
Int Rev Neurobiol; 2016; 130():73-113. PubMed ID: 27678175
[TBL] [Abstract][Full Text] [Related]
19. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
20. Application of modelling and nanotechnology-based approaches: The emergence of breakthroughs in theranostics of central nervous system disorders.
Hassanzadeh P; Atyabi F; Dinarvand R
Life Sci; 2017 Aug; 182():93-103. PubMed ID: 28583367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
